logo
CDC drowning safety team no longer afloat

CDC drowning safety team no longer afloat

Politico27-05-2025
Presented by
With help from Danny Nguyen
Driving The Day
SAFETY NET GONE — Memorial Day, for many, marks the start of the swimming season. This year, the federal team that tracks drowning incidents and issues public water safety alerts has been disbanded, POLITICO's Sophie Gardner reports.
In April, President Donald Trump laid off the team at the CDC responsible for drowning prevention work.
Why it matters: That team regularly publicized the latest statistics for U.S. drowning deaths each May to inform families of the risks and also worked with partners like the YMCA and the American Red Cross to enroll at-risk children in swimming lessons. That collaboration has been halted.
The cuts come as drowning deaths rose during the pandemic, hitting 4,300 in 2023, the most recent data, compared with around 4,000 in 2019. They rose even more among the youngest children, ages 1 to 4, for whom drowning is the No. 1 cause of death — according to the team's previously published numbers.
'I can't tell you how many media calls we got after that report was released because I think it was a shocking number to people, and they wanted to know what's going on,' said Amy Hill, who works on Chicago's water safety task force, referring to a CDC study released last May. 'When the CDC issues a report like that, people pay attention.'
Work halted: States will continue to report drownings through the CDC's National Vital Statistics System, but the data will no longer have a team to analyze it. Two CDC scientists, who spoke with POLITICO on the condition of anonymity for fear of retribution, said the team had been close to publishing a handful of reports before the layoffs — including one on drowning deaths among people with autism.
'The way that this was done means that there [were] a lot of taxpayer dollars that were wasted here because there was work already in process,' a CDC official granted anonymity for fear of retribution told POLITICO about the layoffs. 'We could have done it in a way that did not undermine all of this critical work, especially for something like drowning, that literally nobody else is working on.'
RFK Jr.'s view: At a Senate hearing on Trump's fiscal 2026 budget proposal Tuesday, Health Secretary Robert F. Kennedy Jr. broadly defended downsizing federal health agencies as necessary to stem what he described as bureaucratic bloat that occurred during the Biden administration and to restrain the federal deficit. But he wasn't specifically asked about the cuts to the drowning-prevention team.
'The safety and well-being of all Americans — especially our nation's children — is a top priority for HHS and Secretary Kennedy,' the HHS spokesperson told POLITICO in an email. 'The Department is strongly committed to preventing tragic and preventable deaths, including those caused by drowning.'
The spokesperson did not respond to a follow-up question asking for details.
WELCOME TO TUESDAY PULSE. We hope you had a relaxing Memorial Day weekend! I spent it watching the Indy 500 for the first time. Send your tips, scoops and feedback to ccirruzzo@politico.com and khooper@politico.com and follow along @ChelseaCirruzzo and @Kelhoops.
In Congress
JOHNSON'S SENATE PLEA — When the Senate returns the first week of June to consider the sweeping megabill passed through the House last week, House Speaker Mike Johnson has a plea for GOP senators: Don't make major changes, POLITICO's Gregory Svirnovskiy reports.
'I encourage them to do their work, of course, as we all anticipate,' Johnson told CNN's Jake Tapper on Sunday on 'State of the Union.' 'But to make as few modifications to this package as possible, because remembering that we've got to pass it one more time to ratify their changes in the House. And I have a very delicate balance here, very delicate equilibrium that we've reached over a long period of time. And it's best not to meddle with it too much.'
Why? Jamming the megabill through the House the first time was a Herculean task for Johnson and his allies in leadership. It required a visit from President Donald Trump to the Capitol and careful negotiating by the speaker to bring the chamber's many coalitions aboard. Doing it a second time — with major changes from the Senate side — could prove impossible.
What could change: Key senators are already looking to make modifications, with different factions holding that the bill goes too far in its approach to Medicaid and clean-energy tax credit cuts. Others, such as Sen. Ron Johnson (R-Wis.) and Sen. Rand Paul (R-Ky.), say it doesn't move the ball far enough. Johnson wants to cut spending by roughly $6 trillion instead of the $1.5 trillion in the House bill.
'This is our only chance to reset that to a reasonable pre-pandemic level of spending,' Ron Johnson told Tapper, also on Sunday. 'And again, I think you can do it in the spending that we would eliminate, people wouldn't even notice. But you have to do the work, which takes time.'
'The problem is the math doesn't add up,' Paul told host Shannon Bream on 'Fox News Sunday.' 'They're going to explode the debt by the House says $4 trillion, the Senate's actually been talking about exploding the debt $5 trillion.'
MURTHY ON SOCIAL MEDIA — As lawmakers work to push forward the Trump administration's megabill, former U.S. Surgeon General Vivek Murthy is calling on Congress to implement social media safeguards for children, POLITICO's Amanda Friedman reports.
Why it matters: While the sweeping legislative package has implications for immigration, defense and health care, it gave limited attention to online safety or tech regulation.
'It's the equivalent of putting our kids in cars with no seat belts, with no airbags, and having them drive on roads with no speed limits and no traffic lights,' said Murthy, who served under former Presidents Barack Obama and Joe Biden, during an interview on NBC's 'Meet the Press' that aired Sunday. 'And that is just morally unacceptable. I think Congress has so far failed in its responsibility to protect our kids.'
Efforts to establish rules for platforms popular among young people, like TikTok, Instagram and Snapchat, have long stalled amid industry lobbying and political gridlock.
For a solution, Murthy called on Congress to implement 'real safety standards' for social media platforms, including issuing warning labels so that 'parents and kids are aware of the risks.' Murthy also stressed the importance of increasing data-transparency requirements for platforms, comparing the measure to the historical precedent of auto safety laws.
'Researchers routinely say they can't get the full data about the impact of these platforms on our kids' health from the companies,' Murthy said. 'But just like we did for cars a few decades ago, we'll be putting safety standards that got us seat belts, airbags, crash testing, and those have reduced the number of deaths.'
'But it's not too late,' Murthy said, referring to Congress. 'They need to step up and act now.'
Lobbying
3 MUSKETEERS TAKE ON CAPITOL HILL — Mars Incorporated, the company that manufactures M&Ms, Skittles, Snickers and other popular candies, has hired a lobbying firm prominent in Republican circles as the Trump administration weighs crushing regulations on the artificial foods industry, Danny reports.
A general disclosure filing shows the group hired the Duberstein Group, a lobbying firm founded by Ken Duberstein, who served as chief of staff to former President Ronald Reagan.
The hiring comes as the confectionary industry braces for a crushing blow from the Make America Healthy Again Commission, a brainchild of Health Secretary Robert F. Kennedy Jr., which will unveil a regulatory framework to reel in the food and pharma industries that the group accuses of poisoning children and causing a surge in chronic disease.
It also comes days after the first MAHA commission report, expected to emphasize the dangers of products used and produced by those sectors, but which barely mentioned those industries.
The agrochemical, artificial food and farming industries have emphasized to lawmakers and Kennedy over the past weeks that any regulation could seriously hurt their bottom line. And if the first report is any indication, those lobbying efforts are working.
On the Mars ticket are David Schiappa, a former secretary of the Senate Republican minority; Katherine Winkler Keating, a former chief of staff to Rep. Joseph Crowley (D-N.Y.); Benjamin Howard, the former deputy assistant of legal affairs to President Donald Trump; and Elizabeth Kelley; who was former President Barack Obama's special assistant on economic policy.
WHAT WE'RE READING
NBC News reports on how artificial intelligence can address medical errors.
The Wall Street Journal reports on a study showing that fears about food spoiling could be keeping some people from healthy foods.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID
ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID

Business Wire

timea minute ago

  • Business Wire

ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a significant public health challenge with no currently available established therapies. The new study, called COVID-4.019-Long, further expands the company's clinical research efforts to assess ANKTIVA's potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia. The primary objective of the exploratory, single-arm study (NCT0712372 7) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA's ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells. 'We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.' The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit ANKTIVA is currently approved by the U.S. Food and Drug Administration with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. About Long COVID Long COVID is a serious illness that can cause chronic health conditions requiring comprehensive care. It may also lead to disability. 2 Long COVID impacts approximately 1 in 5 Americans adults who had a previous COVID-19 infection. 1 It can include a wide range of ongoing symptoms and conditions that can last weeks, months, or even years after COVID-19 illness. 1 Some of the common among the more than 200 identified symptoms include fatigue, brain fog, coughing, shortness of breath, heart palpitations and change in smell or taste. 3 Anyone who had a SARS-CoV-2 infection, the virus that causes COVID-19, can experience Long COVID, including children. 1 Long COVID remains a significant public health challenge with no currently available established treatments. About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. A key component in the company's BioShield platform, ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Prescribing Information for ANKTIVA ® at References: Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. May 3 2023;76(9):1636-1645. U.S. Centers for Disease Control and Prevention. Long COVID Basics. July 2025. Available at U.S. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. July 2025. Available at About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the potential health conditions associated with Long COVID, potential patient populations and implications thereof, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

U.S. pediatricians' new COVID-19 shot recommendations differ from CDC advice
U.S. pediatricians' new COVID-19 shot recommendations differ from CDC advice

NBC News

time2 minutes ago

  • NBC News

U.S. pediatricians' new COVID-19 shot recommendations differ from CDC advice

For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine recommendations. The group's new COVID-19 recommendations — released Tuesday — come amid a tumultuous year for public health, as vaccine skeptics have come into power in the new Trump administration and government guidance has become increasingly confusing. This isn't going to help, acknowledged Dr. James Campbell, vice chair of the AAP infectious disease committee. 'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. That differs from guidance established under U.S. Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient.

In break with current CDC recommendations, leading pediatrics group recommends Covid-19 shots for young children
In break with current CDC recommendations, leading pediatrics group recommends Covid-19 shots for young children

CNN

timean hour ago

  • CNN

In break with current CDC recommendations, leading pediatrics group recommends Covid-19 shots for young children

The American Academy of Pediatrics released its updated recommendations for vaccines on Tuesday, including Covid-19 shots for infants and young children – a break from the current US for Centers for Disease Control and Prevention recommendations. 'It differs from recent recommendations of the Advisory Committee on Immunization Practices of the CDC, which was overhauled this year and replaced with individuals who have a history of spreading vaccine misinformation,' the AAP said in a news release. Current CDC recommendations for the Covid-19 vaccine for children ages 6 months to 17 years should be 'based on shared clinical decision-making,' the agency says. The AAP recommendations are more explicit. It says that all children ages 6 through 23 months should receive a Covid-19 vaccine unless they have known allergies to the vaccine or its ingredients. It also recommends a single dose of the vaccine for children ages 2 through 18 years if they are at high risk of Covid-19, residents of long-term care facilities, have never been vaccinated against Covid-19, or live in a household with people who are high risk for Covid-19. It also says that the vaccine should be available for this age group even if they are in these risk groups. Despite these recommendations, access to the vaccine may be difficult in the fall. The US Food and Drug Administration has said it may limit future Covid-19 shots to older people and those who are at high risk for serious infection, and may not renew authorization for Pfizer's Covid-19 vaccine for children younger than 5 years old. The AAP also issued updated recommendations for RSV and flu vaccines, in addition to more than 10 other vaccines. 'The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children and adolescents,' AAP President Dr. Susan J. Kressly in the said in the news release. 'Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store